Press Release

Press Inquiries Contact
ICR
Revance@icrinc.com

27

February

2023

Revance to Participate in the 43rd Annual Cowen Healthcare Conference

23

February

2023

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting

21

February

2023

Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

09

January

2023

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

06

January

2023

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

22

November

2022

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference